title: Effect kinetics of desmopressin-induced platelet retention in healthy volunteers treated with aspirin or placebo.
abstract: Desmopressin is often used for haemostatic treatment in platelet dysfunction, but the effect kinetics of platelet responses and the mechanism of action are poorly known. This study aimed to determine the kinetics of platelet function responses induced by desmopressin in healthy volunteers treated with aspirin or placebo. Another aim was to correlate platelet responses to changes of von Willebrand factor (vWF) in plasma. We measured platelet function with a glass bead retention test, Ivy bleeding time, vWF:Ag and multimeric structure in plasma. Median baseline platelet retention was 12% (normal reference range 16-27%) during aspirin treatment and 18% during placebo. Median peak platelet retention after desmopressin was 33% during aspirin treatment and 34% during placebo. After about 3 h platelet function had returned to baseline. A second desmopressin dose after 3 h stimulated platelet retention to a similar extent as the first dose. There was no correlation between platelet responses and quantitative or qualitative changes of vWF in plasma. Platelet count did not change significantly. Thus, desmopressin's effect on platelet function lasts for about 3 h, but may be prolonged by a second dose immediately thereafter. These findings may have important clinical implications for patients with aspirin-induced platelet dysfunction undergoing surgery.
authors.affiliation: Department for Coagulation Disorders, University of Lund, S-205 02 Malmö, Sweden. stefan.lethagen@medforsk.mas.lu.se
authors.forename: S
authors.initials: S
authors.lastname: Lethagen
authors.forename: L
authors.initials: L
authors.lastname: Olofsson
authors.forename: K
authors.initials: K
authors.lastname: Frick
authors.forename: E
authors.initials: E
authors.lastname: Berntorp
authors.forename: S
authors.initials: S
authors.lastname: Björkman
mesh_terms: D000328:Adult; D000941:Antigens / Q000097:blood; D001241:Aspirin / Q000008:administration & dosage*; D001760:Bleeding Time; D018592:Cross-Over Studies; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004311:Double-Blind Method; D005260:Female; D006490:Hemostatics; D006801:Humans; D007700:Kinetics; D008297:Male; D010919:Placebos / Q000008:administration & dosage; D010973:Platelet Adhesiveness / Q000187:drug effects*; D010976:Platelet Count / Q000187:drug effects; D010979:Platelet Function Tests; D020836:Protein Structure, Quaternary / Q000187:drug effects; D014841:von Willebrand Factor / Q000737:chemistry / Q000187:drug effects / Q000276:immunology
chemical_list: D000941:Antigens; D006490:Hemostatics; D010919:Placebos; D014841:von Willebrand Factor; D003894:Deamino Arginine Vasopressin; D001241:Aspirin